NEKTAR THERAPEUTICS Quarterly Costs and Expenses in USD from Q1 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Nektar Therapeutics quarterly/annual Costs and Expenses history and growth rate from Q1 2010 to Q3 2024.
  • Nektar Therapeutics Costs and Expenses for the quarter ending September 30, 2024 was $58.5M, a 15.3% decline year-over-year.
  • Nektar Therapeutics Costs and Expenses for the twelve months ending September 30, 2024 was $246M, a 33.6% decline year-over-year.
  • Nektar Therapeutics annual Costs and Expenses for 2023 was $354M, a 24.4% decline from 2022.
  • Nektar Therapeutics annual Costs and Expenses for 2022 was $468M, a 14.6% decline from 2021.
  • Nektar Therapeutics annual Costs and Expenses for 2021 was $548M, a 5.19% decline from 2020.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $246M $58.5M -$10.5M -15.3% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-08
Q2 2024 $257M $73.3M +$2.17M +3.05% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-09
Q1 2024 $255M $57.1M -$99.2M -63.5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-10
Q4 2023 $354M $57.4M -$17.1M -23% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-05
Q3 2023 $371M $69M -$8.92M -11.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-08
Q2 2023 $380M $71.1M -$103M -59.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-09
Q1 2023 $483M $156M +$14.9M +10.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-10
Q4 2022 $468M $74.5M -$63.4M -46% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-05
Q3 2022 $532M $77.9M -$60.6M -43.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $592M $174M +$35.9M +25.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $556M $141M +$8.34M +6.27% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $548M $138M +$3.74M +2.78% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-05
Q3 2021 $544M $139M +$5.43M +4.08% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-04
Q2 2021 $539M $139M +$12M +9.47% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-05
Q1 2021 $527M $133M -$51.2M -27.8% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q4 2020 $578M $134M -$9.32M -6.49% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 $587M $133M +$5.13M +4.01% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-05
Q2 2020 $582M $127M -$7.73M -5.76% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-06
Q1 2020 $590M $184M +$35.3M +23.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q4 2019 $555M $144M +$3.38M +2.41% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 $551M $128M +$1.56M +1.24% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 $550M $134M +$20.2M +17.7% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-07
Q1 2019 $530M $149M +$24.2M +19.4% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08
Q4 2018 $505M $140M +$20.6M +17.3% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-26
Q3 2018 $485M $126M +$43M +51.5% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 $442M $114M +$28.9M +33.9% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 $413M $125M +$45.6M +57.6% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $367M $120M +$49.9M +71.7% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-28
Q3 2017 $317M $83.4M +$14.2M +20.5% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 $303M $85.2M +$14.2M +19.9% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 $289M $79.2M +$10.8M +15.8% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
Q4 2016 $278M $69.6M +$861K +1.25% Oct 1, 2016 Dec 31, 2016 10-K 2019-03-01
Q3 2016 $277M $69.2M +$9.7M +16.3% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-08
Q2 2016 $268M $71.1M +$4.96M +7.51% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-09
Q1 2016 $263M $68.4M +$2.61M +3.97% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q4 2015 $260M $68.7M +$11.7M +20.5% Oct 1, 2015 Dec 31, 2015 10-K 2018-03-01
Q3 2015 $248M $59.5M +$6.98M +13.3% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-04
Q2 2015 $241M $66.1M +$14.7M +28.6% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-04
Q1 2015 $227M $65.8M +$9.59M +17.1% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-04
Q4 2014 $217M $57M -$10M -14.9% Oct 1, 2014 Dec 31, 2014 10-K 2017-03-01
Q3 2014 $227M $52.6M -$14.9M -22.1% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-06
Q2 2014 $242M $51.4M -$15M -22.6% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-06
Q1 2014 $257M $56.2M -$11.9M -17.5% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-01
Q4 2013 $269M $67M +$2.52M +3.9% Oct 1, 2013 Dec 31, 2013 10-K 2016-03-01
Q3 2013 $267M $67.4M +$16.1M +31.4% Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-07
Q2 2013 $250M $66.5M +$15.8M +31.2% Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-01
Q1 2013 $235M $68.1M +$12.2M +21.9% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-08
Q4 2012 $222M $64.5M +$14.3M +28.4% Oct 1, 2012 Dec 31, 2012 10-K 2015-02-26
Q3 2012 $208M $51.3M +$2.91M +6% Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-07
Q2 2012 $205M $50.7M -$923K -1.79% Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-09
Q1 2012 $206M $55.9M +$10.7M +23.7% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-09
Q4 2011 $195M $50.3M -$15.6M -23.7% Oct 1, 2011 Dec 31, 2011 10-K 2012-02-29
Q3 2011 $211M $48.4M +$4.26M +9.64% Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-09
Q2 2011 $207M $51.6M +$10.9M +26.8% Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-09
Q1 2011 $196M $45.2M +$8.57M +23.4% Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-04
Q4 2010 $187M $65.9M Oct 1, 2010 Dec 31, 2010 10-K 2012-02-29
Q3 2010 $44.2M Jul 1, 2010 Sep 30, 2010 10-K 2012-02-29
Q2 2010 $40.7M Apr 1, 2010 Jun 30, 2010 10-K 2012-02-29
Q1 2010 $36.6M Jan 1, 2010 Mar 31, 2010 10-K 2012-02-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.